Arthur Levinson became Chairman and Chief Executive Officer of
Genentech in July 1995. Levinson was appointed a member of the board of
directors that same year and was named chairman of the board in 1999.
Levinson
joined the company in 1980 as a senior scientist and subsequently held
the position of staff scientist and director of Cell Genetics at
Genentech. He became vice president of Research Technology in 1989,
vice president of Research in 1990, senior vice president of Research
in 1992, and senior vice president of Research and Development in 1993.
He has been a member of Genentech's executive committee since 1990.
Prior to his employment with Genentech, Levinson was a postdoctoral
fellow in the department of microbiology at the University of
California, San Francisco.
During his career, Levinson
has served on the editorial boards of Molecular Biology and Medicine,
Molecular and Cellular Biology, The Journal of Virology, and Virology.
He also served on the boards of the Pharmaceutical Research and
Manufacturers of America, the Biotechnology Industry Organization, and
the California Healthcare Institute. Levinson has authored or
co-authored more than 80 scientific articles and has been a named
inventor on 11 United States patents, including inventions in the
research of production of recombinant proteins.
Levinson is
a member of the American Society of Microbiology and the American
Society for Biochemistry and Molecular Biology. Levinson sits on the
board of scientific consultants for the Memorial Sloan-Kettering Cancer
Center and is a member of the advisory councils for the California
Institute for Quantitative Biomedical Research (QB3), the Princeton
University Department of Molecular Biology, and the Lewis-Sigler
Institute for Integrative Genomics, also at Princeton. He also serves
on the board of the Technology Network.
Levinson serves on the corporate boards of Apple Inc. and Google Inc.
Levinson
received the Irvington Institute's 1999 Corporate Leadership Award in
Science and was honored the same year with the Corporate Leadership
Award from the National Breast Cancer Coalition.
